Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sky Century InvestmentSKYI -9.13%29 Net Margin % is -10.53% as of May. 2026. GuruFocus rates SKYI with a GF Score™ of 29/100. The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Sky Century Investment ranks worse than 86.44% on this metric.
Sky Century Investment (OTCPK:SKYI) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sky Century Investment Net Margin % Related Terms
Sky Century Investment Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sky Century Investment's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sky Century Investment Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sky Century Investment's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sky Century Investment's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sky Century Investment (SKYI) has a Net Margin % of -10.53% as of May. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sky Century Investment and its competitors. According to the industry distribution chart, Sky Century Investment ranks #829 out of 959 companies in the Drug Manufacturers industry, placing it in the top 86.4%.
Is Sky Century Investment's Net Margin % too high?
Sky Century Investment's current Net Margin % is -10.53%. Based on the distribution chart, Sky Century Investment ranks #829 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sky Century Investment has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Sky Century Investment's Net Margin % compare to SHPH and PLSH?
According to the Drug Manufacturers industry distribution chart, Sky Century Investment ranks #829 out of 959 companies for Net Margin %. This places Sky Century Investment in the lower half of its industry. The industry median Net Margin % is 5.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.32, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sky Century Investment and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sky Century Investment's current Net Margin % is -10.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sky Century Investment stock overvalued right now?
Sky Century Investment (SKYI) has a current Net Margin % of -10.53%. The current Net Margin % is -10.53%. Sky Century Investment's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sky Century Investment (SKYI), the current Net Margin % is -10.53% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sky Century Investment Inc operates four primary business lines, with profits generated from IT Services, including Technical Support and Server Leasing, and from the sale of RSS feeds and Podcasts. The IT Services segment provides ongoing technical support, maintenance, system upgrades, and high-performance server leasing, supporting growing demand for cloud solutions, data management, and network infrastructure. The Company also owns the Cannabis News application, a mobile platform that aggregates cannabis-related news from diverse sources and delivers real-time updates, though it is not commercially viable and has not generated revenue to date. The Company operates in competitive markets across IT services, marketing services, RSS feed services, and the cannabis industry.
29GF Score
Get the complete analysis for SKYI
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SKYI has been successfully added to your 
